US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Brookfield Real Assets Income Fund Inc.

13.22

+0.13000.99%

Post-market: 13.220.00000.00%17:48 EST

Volume:273.03K

Turnover:3.60M

Market Cap:730.47M

PE:9.40

High:13.24

Open:13.11

Low:13.11

Close:13.09

52wk High:13.59

52wk Low:11.87

Shares:55.25M

Float Shares:55.25M

Volume Ratio:1.06

T/O Rate:0.49%

Dividend:1.53

Dividend Rate:11.60%

EPS(TTM):1.41

ROE:--

ROA:--

PB:0.92

PE(LYR):- -

Loading ...

Overview Company News Filings

CPF vs REITs: Which Builds a Stronger Retirement Income Stream in 2026?

The Smart Investor

Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

Press Release: Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2

Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib (LNK01001) in Rheumatoid Arthritis

Philogen Advances Early RA Trial With F8IL10, Signaling Continued Pipeline Progress

Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones

KLMBio Accelerates Global Expansion in Bone Graft Market with Human Tissue-Based Medical Devices

Brookfield Real Assets Income Fund Inc. announces $0.1180 monthly distribution for Q1 2026

Brookfield Real Assets Income Fund Announces Q1 2026 Monthly Distributions

Press Release: Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors

Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)

Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

CPF vs Dividend Stocks: Which Builds a Stronger Retirement Portfolio?

The Smart Investor

Press Release: Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

Brookfield Real Assets Income Fund Inc. Announces Portfolio Manager Update Webcast

Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","market":"US","secType":"STK","nameCN":"Brookfield Real Assets Income Fund Inc.","latestPrice":13.22,"timestamp":1770411600000,"preClose":13.09,"halted":0,"volume":273027,"hourTrading":{"tag":"盘后","latestPrice":13.22,"preClose":13.22,"latestTime":"17:48 EST","volume":16,"amount":211.46,"timestamp":1770418094895,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.009931245225362931,"floatShares":55245934,"shares":55254696,"eps":1.406,"marketStatus":"Market Closed","change":0.13,"latestTime":"02-06 16:00:00 EST","open":13.11,"high":13.24,"low":13.11,"amount":3601486.844,"amplitude":0.009931,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.406,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":13.09,"dividendRate":0.116044,"preHourTrading":{"tag":"盘前","latestPrice":13.09,"preClose":13.09,"latestTime":"08:00 EST","volume":6,"amount":78.548496,"timestamp":1770382808912,"change":0,"changeRate":0,"amplitude":0.00013},"postHourTrading":{"tag":"盘后","latestPrice":13.22,"preClose":13.22,"latestTime":"17:48 EST","volume":16,"amount":211.46,"timestamp":1770418094895,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.0643813700758773},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","floatShares":55245934,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.0643813700758773,"shares":55254696,"dividePrice":1.5341,"high":13.24,"amplitude":0.009931,"preClose":13.09,"low":13.11,"week52Low":11.87,"pbRate":"0.92","week52High":13.59,"institutionHeld":0,"latestPrice":13.22,"eps":1.406,"divideRate":0.116044,"volume":273027,"delay":0,"ttmEps":1.406,"open":13.11,"prevYearClose":12.96,"prevWeekClose":13.02,"prevMonthClose":13.02,"prevQuarterClose":12.96,"fiveDayClose":13.02,"twentyDayClose":12.83,"sixtyDayClose":13.26},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RA\",params:#limit:5,,,undefined,":[{"date":"2026-03-12","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-12","defaultRemindTime":1773322200000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-26","payableDate":"2026-03-12","currency":"USD","dateTimestamp":1773288000000,"payDate":"2026-03-26"},{"date":"2026-02-05","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-02-05","defaultRemindTime":1770301800000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-19","payableDate":"2026-02-05","currency":"USD","dateTimestamp":1770267600000,"payDate":"2026-02-19"},{"date":"2026-01-08","symbol":"RA","amount":0.118,"announcedDate":"2025-12-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-08","defaultRemindTime":1767882600000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-22","payableDate":"2026-01-08","currency":"USD","dateTimestamp":1767848400000,"payDate":"2026-01-22"},{"date":"2025-12-11","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-11","defaultRemindTime":1765463400000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-11","currency":"USD","dateTimestamp":1765429200000,"payDate":"2025-12-26"},{"date":"2025-11-13","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-11-13","defaultRemindTime":1763044200000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-11-28","payableDate":"2025-11-13","currency":"USD","dateTimestamp":1763010000000,"payDate":"2025-11-28"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RA\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-13","recordDate":"2016-12-15","paymentDate":"2016-12-22","value":0.199,"currency":"USD"},{"executeDate":"2017-03-14","recordDate":"2017-03-16","paymentDate":"2017-03-23","value":0.199,"currency":"USD"},{"executeDate":"2017-04-18","recordDate":"2017-04-20","paymentDate":"2017-04-27","value":0.199,"currency":"USD"},{"executeDate":"2017-05-16","recordDate":"2017-05-18","paymentDate":"2017-05-25","value":0.199,"currency":"USD"},{"executeDate":"2017-06-13","recordDate":"2017-06-15","paymentDate":"2017-06-22","value":0.199,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2603262769","title":"CPF vs REITs: Which Builds a Stronger Retirement Income Stream in 2026?","url":"https://stock-news.laohu8.com/highlight/detail?id=2603262769","media":"The Smart Investor","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603262769?lang=en_us&edition=fundamental","pubTime":"2026-01-15 11:30","pubTimestamp":1768447800,"startTime":"0","endTime":"0","summary":"CPF offers certainty and safety, while REITs provide higher income potential. As retirement planning evolves in 2026, we compare how each stacks up as a long-term income stream.","market":"nz","thumbnail":"https://thesmartinvestor.com.sg/wp-content/uploads/2026/01/CPF-Vs-REITs-300x200.png","type":0,"news_type":0,"thumbnails":["https://thesmartinvestor.com.sg/wp-content/uploads/2026/01/CPF-Vs-REITs-300x200.png"],"rights":{"source":"thesmartinvestor_highlight","url":"https://thesmartinvestor.com.sg/cpf-vs-reits-which-builds-a-stronger-retirement-income-stream-in-2026/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thesmartinvestor.com.sg/cpf-vs-reits-which-builds-a-stronger-retirement-income-stream-in-2026/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thesmartinvestor_highlight","symbols":["BK4017","BK6082","AJBU.SI","BK6011","BK6131","CPF","BK6133","BUOU.SI","BK6014","BK6137","BK6512","CFA.SI","CFA","C38U.SI","RA","BK6072","BK4211"],"gpt_icon":0},{"id":"2603686974","title":"Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2603686974","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603686974?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:00","pubTimestamp":1768305600,"startTime":"0","endTime":"0","summary":"KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027  KT-579 Phase 1 HV clinical trial expect","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/13/3217633/0/en/Kymera-Therapeutics-Outlines-Key-2026-Objectives-and-Strategy-to-Advance-Industry-Leading-Portfolio-of-Oral-Immunology-Programs.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BP","BK4096","AD","LU1829250122.USD","BK4139","EASI","LU0162691827.USD","LU0320765646.SGD","IBD","PN","RA","LU1162221912.USD","BK4201","BK4585","LU0072461881.USD","BK4132","BK4588"],"gpt_icon":0},{"id":"2602510876","title":"Press Release: Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510876","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510876?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222800,"startTime":"0","endTime":"0","summary":"\"6 in '26\" expected proof-of-concept  readouts across SKYLINE and SKYWAY trials. SKYLINE platform trial in ulcerative colitis  recruiting faster than expected with SPY001 enrollment complete ahead of schedule; Part A readouts accelerated, now expected to start in Q2. SKYWAY basket trial enrollment on track across rheumatoid arthritis , psoriatic arthritis , and axial spondyloarthritis ; All readouts expected in 4Q 2026. WALTHAM, Mass., Jan. 12, 2026  -- Spyre Therapeutics, Inc. , a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease  and rheumatic diseases, today highlighted its 2026 priorities including six expected POC readouts . The Company also expanded its leadership team with the appointment of Kate Tansey Chevlen as CCO. Ms. Tansey Chevlen is a seasoned biopharma commercial leader with nearly two decades of experience driving strategy, execution, and growth across U.S. an","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2294711713.HKD","SYRE","BK4539","CCO","LU0823414478.USD","LU0823414551.USD","BK4007","BK4139","LU2357125470.USD","LU2249611893.SGD","RA","LU2506951792.HKD","BK4009","LENZ"],"gpt_icon":0},{"id":"2602565191","title":"Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib (LNK01001) in Rheumatoid Arthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2602565191","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602565191?lang=en_us&edition=fundamental","pubTime":"2026-01-12 08:00","pubTimestamp":1768176000,"startTime":"0","endTime":"0","summary":"HANGZHOU, China, SHANGHAI and BOSTON, Jan. 12, 2026 /PRNewswire/ --Lynk Pharmaceuticals Co., Ltd. , a clinical stage innovative drug development company focused on developing innovative therapies for immune and inflammatory diseases, today announced positive topline results from its Phase III clinical trial evaluating zemprocitinib  in patients with moderate to severe active rheumatoid arthritis . The study met its primary and key secondary efficacy endpoints, demonstrating statistically significant improvements versus placebo , with a favorable safety and tolerability profile.Professor Xiaofeng Zeng, the principal investigator of this study from Peking Union Medical College Hospital and Chinese Academy of Medical Sciences, said: \"Rheumatoid arthritis is a chronic, progressive autoimmune disease that can severely impact patients' quality of life and physical health. In this Phase III study, zemprocitinib demonstrated strong ef","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/lynk-pharmaceuticals-announces-positive-phase-iii-topline-data-of-zemprocitinib-lnk01001-in-rheumatoid-arthritis-302657982.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZK","BK4134","III","RA","BK4099"],"gpt_icon":0},{"id":"2602308899","title":"Philogen Advances Early RA Trial With F8IL10, Signaling Continued Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2602308899","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602308899?lang=en_us&edition=fundamental","pubTime":"2026-01-10 00:31","pubTimestamp":1767976277,"startTime":"0","endTime":"0","summary":"Philogen SpA ($DE:78Q) announced an update on their ongoing clinical study. Philogen SpA has started a Phase I clinical trial called “A Dose-findin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/philogen-advances-early-ra-trial-with-f8il10-signaling-continued-pipeline-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/philogen-advances-early-ra-trial-with-f8il10-signaling-continued-pipeline-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRGS","BK4097","LU2065732104.USD","RA"],"gpt_icon":0},{"id":"2601841369","title":"Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2601841369","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601841369?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873600,"startTime":"0","endTime":"0","summary":"Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommend","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/08/3215212/0/en/Cullinan-Therapeutics-Provides-Corporate-Update-and-Highlights-Anticipated-2026-Milestones.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","CGEM","BK4139","RA","SLE"],"gpt_icon":0},{"id":"2595252728","title":"KLMBio Accelerates Global Expansion in Bone Graft Market with Human Tissue-Based Medical Devices","url":"https://stock-news.laohu8.com/highlight/detail?id=2595252728","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595252728?lang=en_us&edition=fundamental","pubTime":"2025-12-31 12:44","pubTimestamp":1767156240,"startTime":"0","endTime":"0","summary":"SEOUL, South Korea, Dec. 31, 2025 /PRNewswire/ --KLMBio, a manufacturer and exporter of human tissue-based medical devices, is accelerating its global business expansion by strengthening its high-value tissue-based product portfolio to target the rapidly growing global bone graft market.The global bone graft market is a high-growth medical device sector, driven by steadily increasing usage in orthopedic surgery, spinal procedures, and dental implants. The market is projected to reach approximately USD 6.66 billion by 2032. In particular, human tissue-based products continue to gain market preference and profitability due to their limited supply and consistently strong demand.Looking ahead, KLMBio plans to allocate approximately 40% of its total investment toward expanding production capacity, including the construction of a second manufacturing facility with cleanrooms and additional sterilization, freeze-drying, and packaging equipment. The company will also accelerate the commerciali","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/klmbio-accelerates-global-expansion-in-bone-graft-market-with-human-tissue-based-medical-devices-302651063.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA"],"gpt_icon":0},{"id":"2594137992","title":"Brookfield Real Assets Income Fund Inc. announces $0.1180 monthly distribution for Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2594137992","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594137992?lang=en_us&edition=fundamental","pubTime":"2025-12-27 05:35","pubTimestamp":1766784957,"startTime":"0","endTime":"0","summary":"Brookfield Real Assets Income Fund Inc. announced monthly distributions of $0.1180 per share for January, February, and March 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brookfield Real Assets Income Fund Inc. published the original content used to generate this news brief via GlobeNewswire  on December 26, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251226:nNDL8CNSdY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014021.USD","SG9999014039.USD","LU2095319765.USD","SG9999014013.SGD","LU2210149790.SGD","BK4112","NDAQ","IE00B64PRP62.GBP","LU2210150020.SGD","BK4585","BK4588","LU0314104364.USD","SG9999014005.SGD","IE00BGHQF748.EUR","RA"],"gpt_icon":0},{"id":"2594213791","title":"Brookfield Real Assets Income Fund Announces Q1 2026 Monthly Distributions","url":"https://stock-news.laohu8.com/highlight/detail?id=2594213791","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594213791?lang=en_us&edition=fundamental","pubTime":"2025-12-27 05:35","pubTimestamp":1766784956,"startTime":"0","endTime":"0","summary":"Brookfield Real Assets Income Fund Inc. has announced its monthly distribution schedule for the first quarter of 2026. The fund will pay distributions of $0.1180 per share on January 22, February 19, and March 26, 2026, to shareholders of record on January 8, February 5, and March 12, 2026, respectively.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brookfield Real Assets Income Fund Inc. published the original content used to generate this news brief via GlobeNewswire  on December 26, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251226:nNDL1kvMwX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BKPKM429.USD","BK4585","BK4588","IE00B64PRP62.GBP","LU2210149790.SGD","LU2210150020.SGD","LU0314104364.USD","RA","SG9999014013.SGD","SG9999014039.USD","IE00B3QW5Z07.USD","LU2095319765.USD","BK4112","SG9999014021.USD","SG9999014005.SGD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2593448733","title":"Press Release: Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2593448733","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593448733?lang=en_us&edition=fundamental","pubTime":"2025-12-24 05:01","pubTimestamp":1766523660,"startTime":"0","endTime":"0","summary":"BOSTON, Mass., Dec. 23, 2025  -- Vor Biopharma Inc. , a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Andrew Levin, M.D., Ph.D., Partner at RA Capital Management, and Wouter Joustra, General Partner at Forbion, to its Board of Directors. Their appointments follow the Company's recently announced $150M PIPE financing, which included participation from both investors.\"Andrew and Wouter bring highly complementary experience in life sciences investment, financing strategy, and board-level oversight. We are delighted to welcome them to our Board at an important moment for the Company,\" said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of Vor Bio. \"Their perspectives will be invaluable as we advance our global Phase 3 programs and position the Company to drive long-term shareholder value.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA"],"gpt_icon":0},{"id":"2588988246","title":"Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2588988246","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588988246?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:15","pubTimestamp":1764854100,"startTime":"0","endTime":"0","summary":"APONVIE, an aprepitant product, highlighted as the only FDA-approved IV formulation Neurokinin-1 (“NK-1”) antagonist indicated for the prevention of PONV in adults, with a long half-life and quicker o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/04/3199763/0/en/Heron-Therapeutics-Announces-Inclusion-of-APONVIE-aprepitant-Injectable-Emulsion-in-the-Newly-Released-Fifth-Consensus-Guidelines-for-the-Management-of-Postoperative-Nausea-and-Vom.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HRTX","BK4139","RA"],"gpt_icon":0},{"id":"2583652514","title":"Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2583652514","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583652514?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:01","pubTimestamp":1763067660,"startTime":"0","endTime":"0","summary":"Multiple Late-Stage Data Readouts Reinforce Telitacicept’s Broad Potential Across Autoimmune DiseasesExpansion of Executive Leadership and Board Strengthens Global Development Capabilities Expected gr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/13/3187807/0/en/Vor-Bio-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","BK4077","BK4213","SLE","SD"],"gpt_icon":0},{"id":"2583683055","title":"CPF vs Dividend Stocks: Which Builds a Stronger Retirement Portfolio?","url":"https://stock-news.laohu8.com/highlight/detail?id=2583683055","media":"The Smart Investor","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583683055?lang=en_us&edition=fundamental","pubTime":"2025-11-13 17:30","pubTimestamp":1763026200,"startTime":"0","endTime":"0","summary":"CPF offers guaranteed, risk-free returns, while dividend stocks provide income and long-term growth. Here’s how each can strengthen your retirement portfolio.","market":"sg","thumbnail":"https://thesmartinvestor.com.sg/wp-content/uploads/2025/11/CPF-vs-Dividend-Stocks-300x200.png","type":0,"news_type":0,"thumbnails":["https://thesmartinvestor.com.sg/wp-content/uploads/2025/11/CPF-vs-Dividend-Stocks-300x200.png"],"rights":{"source":"thesmartinvestor_highlight","url":"https://thesmartinvestor.com.sg/cpf-vs-dividend-stocks-which-builds-a-stronger-retirement-portfolio/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thesmartinvestor.com.sg/cpf-vs-dividend-stocks-which-builds-a-stronger-retirement-portfolio/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thesmartinvestor_highlight","symbols":["SGXZ43160589.SGD","LU2238330802.EUR","RA","S68.SI","LU0061475181.USD","LU0823413660.USD","SG9999002406.SGD","LU0345775950.USD","IE00BVYPNP33.GBP","BK4533","LU0823397103.USD","LU0868494708.USD","LU0868494617.USD","STI.SI","SG9999002224.SGD","C2PU.SI","SG9999001424.SGD","CFA.SI","LU0823417653.USD","LU2250418816.HKD","LU0390134368.USD","IE00BFXG0V08.USD","LU0878004406.USD","LU0128522157.USD","IE00BQXX3D17.EUR","CPF","LU0942090050.USD","LU1989764748.USD","IE00BVYPNQ40.USD","IE00BQXX3C00.GBP","LU0205439572.USD","IE00BQXX3F31.USD","LU0441851309.USD","LU0882747503.HKD","LU2456880835.USD","LU0557290698.USD","LU0588545490.SGD","LU2462157665.USD","SG9999000418.SGD","BK6033","LU1551013425.SGD","LU0345769631.USD","MA","LU0276348264.USD","LU0315178854.USD","LU0689472784.USD","LU1119993845.HKD","SGXZ58947870.SGD"],"gpt_icon":1},{"id":"2582734693","title":"Press Release: Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2582734693","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582734693?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948800,"startTime":"0","endTime":"0","summary":"Over 100 patients treated with AlloNK across autoimmune and oncology indications. Refractory rheumatoid arthritis  prioritized as lead indication following FDA Fast Track Designation for AlloNK, the first known therapy within the emerging deep B-cell depletion category to receive this designation in RA. Company to host webcast later this morning to discuss initial safety and translational data from clinical trials evaluating AlloNK in combination with anti-CD20 monoclonal antibodies across autoimmune diseases; presentation to also include outpatient feasibility and tolerability observations. Initial clinical response data in refractory RA expected in the first half of 2026, with FDA discussions planned to align on potential pivotal trial design in refractory RA. Cash runway into Q2 2027, with cash, cash equivalents, and investments of $123.0 million as of September 30, 2025. SAN DIEGO, Nov. 12, 2025  -- Artiva Biotherapeutics, Inc.  , a clinical-stage biotechnology company whose missio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4022","RA","ARTV","BK4232","R"],"gpt_icon":0},{"id":"2582010874","title":"Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2582010874","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582010874?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:35","pubTimestamp":1762781700,"startTime":"0","endTime":"0","summary":"The Company’s operating loss declined by 44% year-over-year, reflecting its continued laser focus on relentless execution and progress in operational excellence Continued progress with lead program, E","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/10/3184603/0/en/Ernexa-Therapeutics-Reports-Strong-Quarterly-Performance-Highlighting-Operational-Execution-and-Progress-Toward-First-in-Human-Cell-Therapy-Trials.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ERNA","BK4539","PRGS","LU2065732104.USD","RA","LENZ","BK4007","PROC","BK4097"],"gpt_icon":0},{"id":"2582865090","title":"Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2582865090","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582865090?lang=en_us&edition=fundamental","pubTime":"2025-11-09 00:45","pubTimestamp":1762620300,"startTime":"0","endTime":"0","summary":"Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with a favorable safety profile Telitacicept demonstrated a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/08/3184078/0/en/Telitacicept-Achieved-Primary-Endpoint-of-Reducing-Proteinuria-in-Stage-A-of-a-Phase-3-Clinical-Study-for-IgA-Nephropathy-in-China.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4017","BK4077","LU1223083913.SGD","SSI","CDE","SLE","RA","LU1223082196.USD","LU1223082519.USD"],"gpt_icon":0},{"id":"2579584751","title":"Brookfield Real Assets Income Fund Inc. Announces Portfolio Manager Update Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2579584751","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579584751?lang=en_us&edition=fundamental","pubTime":"2025-10-30 06:19","pubTimestamp":1761776340,"startTime":"0","endTime":"0","summary":"NEW YORK, Oct.  29, 2025  (GLOBE NEWSWIRE) -- Brookfield Public Securities Group LLC (“PSG”) will host a webcast for Brookfield Real Assets Income Fund Inc. (NYSE: RA) (the “Fund”) on Wednesday, Novem","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/29/3176982/0/en/Brookfield-Real-Assets-Income-Fund-Inc-Announces-Portfolio-Manager-Update-Webcast.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMBS","CMBS","BK4141","RA","BK4585"],"gpt_icon":0},{"id":"2579930188","title":"Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2579930188","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579930188?lang=en_us&edition=fundamental","pubTime":"2025-10-29 23:01","pubTimestamp":1761750060,"startTime":"0","endTime":"0","summary":"Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms 100% of patients on telitacicept for 48 weeks achieved ≥2-point Myasthenia Gravis Activit","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/29/3176649/0/en/Telitacicept-Demonstrates-Sustained-Efficacy-and-Favorable-Safety-Profile-in-48-Week-China-Phase-3-Open-Label-Extension-Generalized-Myasthenia-Gravis-Data.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","BK4178","AAN","BK4077","SLE"],"gpt_icon":0},{"id":"2579790195","title":"Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2579790195","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579790195?lang=en_us&edition=fundamental","pubTime":"2025-10-29 21:15","pubTimestamp":1761743700,"startTime":"0","endTime":"0","summary":"New data reinforce rosnilimab’s efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced thera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/29/3176538/0/en/Anaptys-Announces-New-Positive-Phase-2b-Trial-Results-for-Rosnilimab-in-Rheumatoid-Arthritis-at-ACR-Late-Breaking-Oral-Presentation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","ACR","BK4110"],"gpt_icon":0},{"id":"2578964388","title":"Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2578964388","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578964388?lang=en_us&edition=fundamental","pubTime":"2025-10-27 19:00","pubTimestamp":1761562800,"startTime":"0","endTime":"0","summary":"KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to appro","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/27/3174428/0/en/Kymera-Therapeutics-Presents-New-Preclinical-Data-for-KT-579-a-First-in-Class-Oral-IRF5-Degrader-at-the-American-College-of-Rheumatology-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AFG","BK4115","IBD","BK4139","LU0541502299.USD","RA","BK4117","BK4107","BK4110","ACR","LU0541501648.USD","KT","KYMR"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":35,"code":"91000000","status":"200"}]}}